• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国国立卫生研究院 COVID-19 治疗指南专家组:观点与经验教训。

National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned.

机构信息

Weill Cornell Medicine, New York, New York (R.M.G.).

National Institutes of Health, Bethesda, Maryland (A.K.P., R.R., H.M., H.C.L.).

出版信息

Ann Intern Med. 2024 Nov;177(11):1547-1557. doi: 10.7326/ANNALS-24-00464. Epub 2024 Oct 1.

DOI:10.7326/ANNALS-24-00464
PMID:39348691
Abstract

DESCRIPTION

In March 2020, the White House Coronavirus Task Force determined that clinicians in the United States needed expert treatment guidelines to optimally manage patients with COVID-19, a potentially life-threatening disease caused by a new pathogen for which no specific treatments were known to be effective.

METHODS

The U.S. Department of Health and Human Services requested that the National Institutes of Health (NIH) take the lead in expeditiously convening a panel of experts to create "living" guidelines that would be widely accessible and capable of frequent updating as important new information became available.

RECOMMENDATIONS

The purpose of this article is to expand on the experiences of the NIH COVID-19 Treatment Guidelines Panel (the Panel) over the past 4 years, summarize the Panel's final recommendations for COVID-19, highlight some challenges and unanswered questions about COVID-19 management, and inform future responses to public health emergencies. The Panel was formed in March 2020, and the first iteration of the guidelines was released in April 2020. Now that the public health emergency has ended, the NIH COVID-19 Treatment Guidelines have sunsetted. This role will now fall to professional societies and organizations, such as the American College of Physicians, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the World Health Organization, all of which have been active in this area.

摘要

描述

2020 年 3 月,白宫冠状病毒特别工作组确定,美国临床医生需要专家治疗指南,以最佳方式管理 COVID-19 患者,这种疾病可能危及生命,由一种新病原体引起,目前已知没有有效的特定治疗方法。

方法

美国卫生与公众服务部要求美国国立卫生研究院(NIH)牵头迅速召集一个专家组,制定“活”的指南,以便广泛获取,并能够在有重要新信息时频繁更新。

建议

本文旨在扩大 NIH COVID-19 治疗指南专家组(专家组)在过去 4 年中的经验,总结专家组关于 COVID-19 的最终建议,突出 COVID-19 管理方面的一些挑战和未解决的问题,并为未来应对公共卫生紧急情况提供信息。专家组于 2020 年 3 月成立,指南的第一个版本于 2020 年 4 月发布。随着公共卫生紧急情况的结束,NIH COVID-19 治疗指南已经结束。这一角色现在将由专业协会和组织承担,如美国医师学院、美国传染病学会、儿科传染病学会和世界卫生组织,它们在这一领域一直很活跃。

相似文献

1
National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned.美国国立卫生研究院 COVID-19 治疗指南专家组:观点与经验教训。
Ann Intern Med. 2024 Nov;177(11):1547-1557. doi: 10.7326/ANNALS-24-00464. Epub 2024 Oct 1.
2
Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19.在大流行病健康危机期间制定治疗指南:从 COVID-19 中吸取的教训。
Ann Intern Med. 2021 Aug;174(8):1151-1158. doi: 10.7326/M21-1647. Epub 2021 Jun 15.
3
Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit.美国国立卫生研究院 SARS-CoV-2 抗病毒治疗峰会报告。
J Infect Dis. 2021 Jul 15;224(Supplement_1):S1-S21. doi: 10.1093/infdis/jiab305.
4
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022).美国传染病学会关于 COVID-19 患者治疗和管理的指南(2022 年 9 月)。
Clin Infect Dis. 2024 Jun 27;78(7):e250-e349. doi: 10.1093/cid/ciac724.
5
COVID-19 updates: NIH outpatient treatment guidelines.新型冠状病毒肺炎最新消息:美国国立卫生研究院门诊治疗指南。
Med Lett Drugs Ther. 2022 Feb 21;64(1644):32.
6
Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.HIV暴露儿童和HIV感染儿童机会性感染的预防与治疗指南:美国疾病控制与预防中心、国立卫生研究院、美国传染病学会HIV医学协会、儿科传染病学会及美国儿科学会的建议
MMWR Recomm Rep. 2009 Sep 4;58(RR-11):1-166.
7
ESCMID COVID-19 living guidelines: drug treatment and clinical management.ESCMID COVID-19 临床实践指南:药物治疗和临床管理。
Clin Microbiol Infect. 2022 Feb;28(2):222-238. doi: 10.1016/j.cmi.2021.11.007. Epub 2021 Nov 22.
8
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
9
Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel.恢复期血浆治疗 COVID-19:美国国立卫生研究院 COVID-19 治疗指南专家组的观点。
Ann Intern Med. 2021 Jan;174(1):93-95. doi: 10.7326/M20-6448. Epub 2020 Sep 25.
10
Comparison of WHO versus national COVID-19 therapeutic guidelines across the world: not exactly a perfect match.世界卫生组织与各国 COVID-19 治疗指南比较:并非完全匹配。
BMJ Glob Health. 2024 Apr 22;9(4):e014188. doi: 10.1136/bmjgh-2023-014188.

引用本文的文献

1
Late Administration of Remdesivir, Guided by Antigen Test Results, in a Patient Experiencing Difficulty Weaning From the Ventilator Due to Severe COVID-19 Pneumonia.在一名因重症 COVID-19 肺炎而难以脱机的患者中,根据抗原检测结果指导使用瑞德西韦进行晚期治疗。
Cureus. 2025 Jul 31;17(7):e89181. doi: 10.7759/cureus.89181. eCollection 2025 Jul.
2
The Clinical Value of Inflammatory Indicators at the Time of Secondary Infection After Treatment With Tocilizumab: A Cross-Sectional Study.托珠单抗治疗后继发感染时炎症指标的临床价值:一项横断面研究
Health Sci Rep. 2025 Jul 27;8(8):e71036. doi: 10.1002/hsr2.71036. eCollection 2025 Aug.
3
Impact of prior COVID-19 infection on perioperative outcomes in non-small cell lung cancer patients: a prospective observational cohort study.
既往新冠病毒感染对非小细胞肺癌患者围手术期结局的影响:一项前瞻性观察性队列研究
Int J Clin Oncol. 2025 Jul 23. doi: 10.1007/s10147-025-02836-9.
4
Comparative Pharmacovigilance Analysis of Approved and Repurposed Antivirals for COVID-19: Insights from EudraVigilance Data.新冠病毒已批准和重新利用的抗病毒药物的比较药物警戒分析:来自欧洲药品管理局药物警戒数据库(EudraVigilance)数据的见解
Biomedicines. 2025 Jun 5;13(6):1387. doi: 10.3390/biomedicines13061387.
5
In Silico Discovery of a Novel Antiviral Scaffold for SARS-CoV‑2 Targeting the Spike Glycoprotein through the Fatty Acid Binding Pocket.通过脂肪酸结合口袋靶向刺突糖蛋白的新型抗SARS-CoV-2病毒支架的计算机发现
ACS Omega. 2025 Jun 4;10(23):24117-24132. doi: 10.1021/acsomega.4c10519. eCollection 2025 Jun 17.
6
Novel colorectal cancer screening methods - opportunities and challenges.新型结直肠癌筛查方法——机遇与挑战
Nat Rev Clin Oncol. 2025 Jun 6. doi: 10.1038/s41571-025-01037-7.
7
Celluloepidemiology-A paradigm for quantifying infectious disease dynamics on a population level.细胞流行病学——一种在人群层面量化传染病动态的范例。
Sci Adv. 2025 May 16;11(20):eadt2926. doi: 10.1126/sciadv.adt2926.
8
Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis.有症状的新冠门诊患者抗病毒治疗的疗效和安全性:网状Meta分析和预算影响分析
Front Pharmacol. 2025 Apr 16;16:1537018. doi: 10.3389/fphar.2025.1537018. eCollection 2025.
9
MMP-9 metalloproteinase and its regulator are not associated with mid-term CT residual abnormalities in patients with COVID-19 pneumonia.基质金属蛋白酶-9及其调节剂与新冠肺炎患者中期CT残留异常无关。
Acta Radiol Open. 2025 Apr 16;14(4):20584601251330563. doi: 10.1177/20584601251330563. eCollection 2025 Apr.
10
Clinical Features of SARS-CoV-2 Infected Patients in a Large Population Cohort from the South-West Region of Romania.罗马尼亚西南部地区一大群队列中感染新型冠状病毒2的患者的临床特征
Curr Health Sci J. 2024 Oct-Dec;50(4):498-507. doi: 10.12865/CHSJ.50.04.04. Epub 2024 Dec 31.